Bulletin
Investor Alert

Gilead Sciences Inc.

NAS: GILD

GO
/marketstate/country/us

After Hours

/zigman2/quotes/210293917/composite

$

76.65

Change

+0.30 +0.39%

Volume

Volume 100,741

Jul 2, 2020, 7:59 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/210293917/composite

Previous close

$ 76.06

$ 76.35

Change

+0.29 +0.38%

Day low

Day high

$75.65

$77.09

Open
Open: 76.31

52 week low

52 week high

$60.89

$85.97

Open

Market cap

$95.77B

Average volume

15.20M

P/E ratio

19.62

Rev. per Employee

$2.02M

EPS

3.89

Dividend

0.68

Div yield

3.56%

Ex dividend date

6/11/20

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/gild

MarketWatch News on GILD

  1. Gilead Discloses Pricing for Covid-19 Drug

    5:26 p.m. June 29, 2020

    - Josh Nathan-Kazis

  2. U.S. Stocks Jump Despite Grim Virus Milestones

    4:38 p.m. June 29, 2020

    - Barbara Kollmeyer

  3. Meet Barron’s Top CEOs of 2020

    9:36 a.m. June 29, 2020

    - Jack Hough

  4. Gilead pricing for remdesivir is 'reasonable,' says SVB Leerink

    9:12 a.m. June 29, 2020

    - Tomi Kilgore

  5. The Joe Biden Portfolio

    8:46 a.m. June 29, 2020

    - Lisa Beilfuss

  6. The Dow Is Soaring Because Boeing Stock Is Flying Again

    8:26 a.m. June 29, 2020

    - Carleton English

  7. Gilead sees cost of remdesivir for private insurance companies will be $520 per vial

    7:07 a.m. June 29, 2020

    - Tomi Kilgore

  8. Gilead sees most remdesivir treatment plans costing $2,340 per patient

    7:06 a.m. June 29, 2020

    - Tomi Kilgore

  9. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/gild

Other News on GILD

  1. Gilead's remdesivir OK'd in Europe for COVID-19

    12:58 p.m. July 3, 2020

    - Seeking Alpha

  2. Arthritis Drug Fails in Study of Covid-19 Patients

    5:47 p.m. July 2, 2020

    - Joseph Walker

  3. Keep an Eye on Royalty Pharma Stock, 2020’s Biggest IPO

    1:02 p.m. July 2, 2020

    - InvestorPlace.com

  4. Pedal to the Metal Leads to Record Rebound

    11:12 a.m. July 2, 2020

    - GuruFocus.com

  5. Gilead's Remdesivir Sold Out Already

    8:22 a.m. July 2, 2020

    - Seeking Alpha

  6. US Indexes Close Higher on the Last Day of June

    4:11 p.m. June 30, 2020

    - GuruFocus.com

  7. 3 Stocks With Low Forward Price-Earnings Ratios

    11:29 a.m. June 30, 2020

    - GuruFocus.com

  8. Wall Street Breakfast: House Hearing On Pandemic Response

    7:05 a.m. June 30, 2020

    - Seeking Alpha

  9. Needham Releases a Hold Rating on Gilead Sciences (GILD)

    6:33 a.m. June 30, 2020

    - SmarterAnalyst

  10. US Indexes Close With Gains Monday

    3:42 p.m. June 29, 2020

    - GuruFocus.com

  11. Gilead Pricing Remdesivir At $2,340 Per Patient

    12:06 p.m. June 29, 2020

    - Seeking Alpha

  12. GILD vs. ILMN: Which Stock Should Value Investors Buy Now?

    11:40 a.m. June 29, 2020

    - Zacks.com

  13. Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient

    12:01 a.m. June 29, 2020

    - Joseph Walker

  14. Loading more headlines...
/news/pressrelease/company/us/gild

Press Releases on GILD

  1. Loading more headlines...

Rates »

Link to MarketWatch's Slice.